Navigation Links
Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
Date:7/23/2009

nnounced in due course.

The Company has sufficient cash at hand to fund operations into August, however the Company will need to raise additional capital to fund its clinical trials and other operating activities, and repay indebtedness in due course. Shareholders should be aware that if the Company's capital raising efforts are unsuccessful, this will have a material adverse effect on the Company's financial position and operations.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company is in a large Phase II clinical trial in GBM, with 13 clinical sites across the U.S. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and for Phase I trials in five other cancers. The Company has started, and is currently enrolling patients in, a Phase I/II trial with DCVax(R) for recurrent metastatic ovarian cancer. The Company's second technology platform, involving antibodies to CXCR4, is at the late pre-clinical development stage.

For further information about clinical sites and Company information please visit the company web site at www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future securities registrations or other filings with the U.S. Securities and Exchange Commission ("SEC"), future treatment of patients with GBM using DCVax(R)-Brain, and other future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such a
'/>"/>

SOURCE Northwest Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Avantium to Deliver Flowrence System to Pacific Northwest National Laboratory (PNNL), USA
2. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
3. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
4. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
5. Oncothyreon to present at Invest Northwest 2009
6. Sirius Genomics to Present at Invest Northwest Conference
7. Northwest Biotherapeutics Secures $700,000 Equity Financing
8. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
9. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
10. Northwest Secures US$1.65 Million Debt Financing
11. Northwest Secures US$1.0 Million Debt Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014 Research ... "Global Cell Culture Market 2014-2018" report to ... Cell culture is the in vitro growth ... as research, cell studies, and biopharmaceutical production. Cell culture ... production. Cell culture instruments and cell culture consumables are ...
(Date:7/24/2014)... California (PRWEB) July 24, 2014 ... to advances in modeling lithium-ion battery storage capacity. ... benefit from a theoretical model created at ... University that predicts how carbon components will ... energy storage emphasizes the urgent need for higher-performance ...
(Date:7/24/2014)... 24, 2014  CorMedix Inc. (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... notice on July 18, 2014 from the NYSE ... the CorMedix plan to regain compliance with continued ... the NYSE-MKT is continuing the Company,s listing and ...
(Date:7/24/2014)... 24, 2014 2014 Deep Research ... is a professional and in-depth research report on ... Sulphate basic information, including its definition, classification, ... This research covers the international market analysis, including ... analysis covering macroeconomic environment & economic situation analysis, ...
Breaking Biology Technology:Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2Getting More Life out of Lithium-ion Batteries 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4
... Valencia (UV) has confirmed that the substance used to hermetically ... was pine resin. The scientists also studied the metallic fragments ... used for iron-working. In 2005, a group of archaeologists ... at Lixus, an ancient settlement founded by the Phoenicians near ...
... CRANBURY, N.J. , Feb. 5 Amicus Therapeutics ... has elected John F. Crowley as Chairman of the ... (CEO), effective immediately.  Mr. Crowley will succeed Donald J. Hayden, ... Board. , "The Board,s decision to elect Mr. Crowley as Chairman ...
... Stuart Lindsay, Arizona State University Regents, professor and director ... has just released the first comprehensive guide to a ... grain of sand. Introduction to Nanoscience (published by ... an emerging discipline which has in recent years, produced ...
Cached Biology Technology:Chemical analyses uncover secrets of an ancient amphora 2Amicus Therapeutics Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board 2Big book explores a small world: Stuart Lindsay's guide to nanoscience 2Big book explores a small world: Stuart Lindsay's guide to nanoscience 3
(Date:7/24/2014)... Scientists at The New York Stem Cell ... to creating a viable cell replacement therapy for ... , For the first time, NYSCF scientists generated ... samples of patients with primary progressive multiple sclerosis ... induce these stem cells into becoming oligodendrocytes, the ...
(Date:7/24/2014)... 2014) Scientists at The New York Stem ... closer to creating a viable cell replacement therapy ... , For the first time, NYSCF scientists ... skin samples of patients with primary progressive multiple ... to induce these stem cells into becoming oligodendrocytes, ...
(Date:7/24/2014)... factors that characterize sustainable university and college programs ... physics teachers. Specifically, one or more faculty members ... combination with institutional motivation and commitment can ensure ... and Math (STEM) teacher shortages are especially acute ... for institutions seeking to increase the number of ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Creating sustainable STEM teacher preparation programs 2
... his research team at the Centre for Stem Cell Research ... ( http://dev.biologists.org/ ) a new and safer way of ... give rise to every tissue of the body. Rapid developments ... way for stem cell scientists to convert specialised cells, such ...
... Just the mention of this iconic spring and early ... drinks and sweet desserts. Researchers interested in learning more ... of strawberries, a strong influence on consumer preferences, is ... texture, and appearance. The goals of a recent ...
... most often as a healthy, convenient food, are also ... plants are highly prized by many as one of ... ambiance in gardens and pool environments. A research ... journal HortTechnology detailed a study of 33 ...
Cached Biology News:Researchers piggyback to safer reprogrammed stem cells 2Analysis of fresh strawberries reveals consumer preferences 2